Alkermes: Lilly to end inhaled insulin deal

Share this article:
Lilly's "AIR" inhaled insulin
Lilly's "AIR" inhaled insulin
iotech firm Alkermes said Friday it expects Eli Lilly to soon back out of its inhaled insulin development deal between the companies.

“Lilly has informed Alkermes that it is evaluating its business case for AIR Insulin and Alkermes expects Lilly to make a decision to discontinue the program in the next week,” Alkermes said in a news release.

According to Alkermes, Lilly has the right to terminate its license to AIR Insulin at its discretion and expects a Lilly decision based on Lilly's “evaluation of its own business prospects.”

AIR Insulin is a developmental inhalable insulin device that fits in the hand and is being designed to be easy for patients to use. A late-stage trial of AIR was slated to wrap in time for NDA submission of the product in 2009, Bryce Carmine, Lilly's global brand director, told MM&M in late 2007.

Last October, Pfizer folded its cards on its inhaled insulin delivery device, Exubera, which took a $2.8 billion chunk out of Pfizer's coffers. Sales of Exubera, knocked for its “bong-like” delivery system, were at just $4 million for the second quarter of 2007.

Following Novo Nordisk's decision to end development of its AERx iDMS inhaled insulin system in January, biotech firm Mannkind now stands alone as the last remaining inhaled insulin player.

In a statement Monday, MannKind maintained it is “absolutely committed” to the continued development of its Technosphere inhaled insulin product, currently in Phase III testing.

“MannKind recognizes that in order to be successful in today's healthcare market a product must offer improved efficacy and safety, not just improved convenience,” the biotech firm said. “The decisions of Eli Lilly and Co. as well as Pfizer and Novo Nordisk to discontinue the development of their inhaled insulin products reinforce this view. None of those products offer any advantages over injectable rapid acting insulin analogs.”
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.